{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:55:54Z","timestamp":1788742554364,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.mce.2024.112337","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T01:03:20Z","timestamp":1722647000000},"page":"112337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice"],"prefix":"10.1016","volume":"593","author":[{"given":"Lijuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xulei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghu","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conghui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2024.112337_bib1","first-page":"1","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.mce.2024.112337_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11030155","article-title":"Insulin resistance across the spectrum of nonalcoholic fatty liver disease","volume":"11","author":"Armandi","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.mce.2024.112337_bib3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.mce.2024.112337_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.mce.2024.112337_bib5","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"issue":"2021","key":"10.1016\/j.mce.2024.112337_bib6","article-title":"Nonalcoholic fatty liver disease and cardiovascular diseases: the heart of the matter","volume":"11","author":"Chiriac","year":"2021","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.mce.2024.112337_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jceh.2019.06.004","article-title":"Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease","volume":"9","author":"Choudhary","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.mce.2024.112337_bib8","first-page":"528","volume":"28","author":"Cusi","year":"2022","journal-title":"In Pract."},{"key":"10.1016\/j.mce.2024.112337_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","article-title":"Chiglitazar: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.mce.2024.112337_bib10","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2024.112337_bib11","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.mce.2024.112337_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.970292","article-title":"The AMPK pathway in fatty liver disease","volume":"13","author":"Fang","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.mce.2024.112337_bib13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.mce.2024.112337_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s10020-023-00721-7","article-title":"Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK\/ACC signaling and inhibiting ferroptosis","volume":"29","author":"Guo","year":"2023","journal-title":"Mol. Med."},{"key":"10.1016\/j.mce.2024.112337_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/546548","article-title":"In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist","volume":"2012","author":"He","year":"2012","journal-title":"PPAR Res."},{"key":"10.1016\/j.mce.2024.112337_bib16","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s11010-021-04057-w","article-title":"The role of FATP1 in lipid accumulation: a review","volume":"476","author":"Huang","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.mce.2024.112337_bib17","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)","volume":"66","author":"Ji","year":"2021","journal-title":"Sci. Bull."},{"key":"10.1016\/j.mce.2024.112337_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19040980","article-title":"Inactivation of SREBP-1a phosphorylation prevents fatty liver disease in mice: identification of related signaling pathways by gene expression profiles in liver and proteomes of peroxisomes","volume":"19","author":"Knebel","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mce.2024.112337_bib19","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR alpha\/gamma agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mce.2024.112337_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mce.2024.112337_bib21","first-page":"533","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.mce.2024.112337_bib22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages(\u2606)","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mce.2024.112337_bib23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.bjp.0706745","article-title":"The PPARalpha\/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats","volume":"148","author":"Li","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2024.112337_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174304","article-title":"Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway","volume":"907","author":"Luo","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2024.112337_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154892","article-title":"Insulin resistance and insulin sensitizing agents","volume":"125","author":"Mastrototaro","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.mce.2024.112337_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161282","article-title":"Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models","volume":"8","author":"Matsukawa","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.mce.2024.112337_bib27","doi-asserted-by":"crossref","first-page":"G979","DOI":"10.1152\/ajpgi.00169.2012","article-title":"PGC-1alpha overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion","volume":"303","author":"Morris","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.mce.2024.112337_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.mce.2024.112337_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13484","article-title":"Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: a pooled data analysis from two phase III trials","volume":"16","author":"Ning","year":"2024","journal-title":"J. Diabetes"},{"key":"10.1016\/j.mce.2024.112337_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.mce.2024.112337_bib31","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.3748\/wjg.v29.i25.3999","article-title":"Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis","volume":"29","author":"Pal","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.mce.2024.112337_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mce.2024.112337_bib33","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.mce.2024.112337_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mce.2024.112337_bib35","doi-asserted-by":"crossref","first-page":"E730","DOI":"10.1152\/ajpendo.00225.2016","article-title":"Treatment of nonalcoholic fatty liver disease: role of AMPK","volume":"311","author":"Smith","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2024.112337_bib36","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mce.2024.112337_bib37","doi-asserted-by":"crossref","first-page":"10751","DOI":"10.1096\/fj.201902476R","article-title":"PGC1alpha protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response","volume":"34","author":"Wan","year":"2020","journal-title":"Faseb. J."},{"key":"10.1016\/j.mce.2024.112337_bib38","article-title":"Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.mce.2024.112337_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.mce.2024.112337_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154798","article-title":"Fenofibrate, a PPARalpha agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy","volume":"120","author":"Yoo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.mce.2024.112337_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104984","article-title":"Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies","volume":"159","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mce.2024.112337_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000501851","article-title":"Rodent models of nonalcoholic fatty liver disease","volume":"101","author":"Zhong","year":"2020","journal-title":"Digestion"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030372072400193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030372072400193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T16:55:57Z","timestamp":1726160157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030372072400193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"alternative-id":["S030372072400193X"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2024.112337","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2024.112337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112337"}}